Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$1.14 USD
+0.03 (2.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.13 -0.01 (-0.88%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Lineage Cell Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 9 | 15 | 4 | 2 | 4 |
Cost Of Goods | 1 | 1 | 1 | 0 | 0 |
Gross Profit | 8 | 14 | 3 | 1 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 33 | 37 | 52 | 28 | 42 |
Income After Depreciation & Amortization | -25 | -23 | -49 | -26 | -39 |
Non-Operating Income | 0 | -3 | 6 | 5 | 18 |
Interest Expense | -2 | 0 | 0 | 0 | -2 |
Pretax Income | -23 | -26 | -43 | -22 | -19 |
Income Taxes | -2 | 1 | 0 | -1 | -7 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -21 | -26 | -43 | -21 | -12 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -21 | -26 | -43 | -21 | -12 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -24 | -22 | -48 | -25 | -36 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 2 | 3 |
Income After Depreciation & Amortization | -25 | -23 | -49 | -26 | -39 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 172.66 | 169.79 | 164.50 | 150.04 | 145.53 |
Diluted EPS Before Non-Recurring Items | -0.12 | -0.15 | -0.19 | -0.13 | 0.14 |
Diluted Net EPS (GAAP) | -0.12 | -0.15 | -0.26 | -0.14 | -0.08 |
Fiscal Year end for Lineage Cell Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 2.09 | 1.25 | 3.23 | 2.39 |
Cost Of Goods | NA | 0.26 | 0.17 | 0.13 | 0.12 |
Gross Profit | NA | 1.83 | 1.08 | 3.10 | 2.27 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 8.20 | 7.78 | 8.12 | 8.91 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -6.37 | -6.70 | -5.02 | -6.64 |
Non-Operating Income | NA | 1.24 | -0.45 | -0.18 | 0.44 |
Interest Expense | NA | -1.63 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -4.71 | -7.16 | -5.20 | -6.21 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | -1.80 |
Minority Interest | NA | 0.06 | -0.05 | 0.03 | -0.03 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.71 | -7.16 | -5.20 | -4.40 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.78 | -7.11 | -5.23 | -4.37 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 172.66 | 174.87 | 170.59 | 170.13 |
Diluted EPS Before Non-Recurring Items | NA | -0.03 | -0.04 | -0.03 | -0.03 |
Diluted Net EPS (GAAP) | NA | -0.02 | -0.04 | -0.03 | -0.03 |